About Stanmore Implants Management Team

Brian Steer - Executive Chairman

Brian Steer’s experience spans forty years of management within the healthcare industry including twenty years with Baxter Healthcare, which he joined in 1963, holding several positions within the International Division including President of Europe. He spent a further 10 years as President of Zimmer International, a Bristol Myers Squibb company. In 1993 he formed Steer Associates, consulting for Orthofix, Gyrus, Genetics Institute and others.

He later became Director and Chief Operating Officer of Orthofix. In 1995 he led a buy-in/ buy-out of Cremascoli, an Italian orthopaedic company, subsequently sold to Warburg Pincus. He joined Gyrus in 1997 and was executive chairman until Gyrus was sold to Olympus in 2008.

Dr Paul Unwin PhD - CEO & General Manager

Paul joined Stanmore Implants in 1996, he is an authority on limb-salvage implants, and a board member of the International Society On Limb Salvage (ISOLS).

He has extensive experience of product design, development, regulatory approval, manufacturing and commercial operations in the orthopaedic implant area. Prior to joining Stanmore Implants he worked with AEA Technology and holds a PhD in Biomedical Engineering from University College London.

Andrew Jones - Group Sales and Marketing Director

Andrew has over 21 years' experience in the medical devices industry with specific expertise in medical sales and marketing. Most of this experience was gained at Stryker where Andrew spent over 10 years at Director level. Andrew has a real passion for driving new ventures and implementing them with great success. He has helped achieve market share growth in all areas of orthopaedics and is focused on generating the highest levels of customer loyalty.

Andrew is responsible for all group sales and marketing activities along with all areas of customer services.

Eric Dodd - Group Chief Financial Officer

Eric has over 19 years experience in financial positions with major companies, including GlaxoSmithKline plc. He joins Stanmore from Antisoma, a European biotechnology company focused on oncology, where he spent three years as Chief Financial Officer. Prior to this he was Group Finance Director for Morse plc, a British IT consultancy group with operations across Europe and a turnover of £300m.

From 1992 Eric spent four years at Deloitte & Touche where he qualified as a Chartered Accountant. He has a BEng hons degree in Manufacturing Engineering and Management from Loughborough University and an MBA from London Business School.

Graeme Brookes - Managing Director - CAS/Integrated Technologies

Graeme Brookes has over 25 years experience in the medical devices industry covering fields as diverse as nuclear medicine, woundcare, electrotherapy, neurosurgery and orthopaedics. He spent 9 years with Johnson & Johnson in senior roles within sales & marketing where he also led licensing & acquisition activities as a European board member of the orthopaedic and neurosurgical franchises. More recently he was Chief Executive Officer at The Acrobot Company Ltd, where he raised venture capital finance to fund product and business development and managed the trade sale of the company to Stanmore Implants in August 2010.

He is currently Managing Director for the Computer Assisted Surgery (CAS) / Integrated Technology business within Stanmore Implants, which is responsible for the development and commercialisation of the Savile Row system.

Bruce Steer - CEO - ITAP

Bruce has been with the company for over three years and previously ran his own successful dental surgical supply business. Bruce ran this business for over 14 years having gained significant market share and customer loyalty. Bruce is now heading up a team responsible for the development and commercialisation of the ITAP project to provide transdermal implants for amputees.

Prof Gordon Blunn PhD - Scientific Consultant

Gordon Blunn has extensive experience in orthopaedic medical devices, materials and musculo-skeletal tissues. Gordon has led many successful research projects funded by government bodies and orthopaedic companies and has established a team of dynamic researchers, some of whom are focused on enhancing massive endoprosthetic replacements.